Dynamix Pharmaceuticals Inc.

Optimization of a lead drug candidate often takes a few years, as companies assess hundreds and sometimes thousands of compounds, seeking just one with the best overall pharmacological profile. By contrast, Dynamix Pharmaceuticals Ltd. says its structure-based discovery approach dubbed DynamixFit has let the firm select lead molecules with less than 100 compounds synthesized in under two years. Dynamix aims to apply its techniques on two main tracks: first, to discover drug candidates that intervene with the metabolism of cancer cells; and second, to selectively target specific cellular signaling pathways mediated by Type II kinase inhibitors.